Medicare Enrolled
Dr. James Stocks, M.D.
Urology Physician · Cypress, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Stocks from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Stocks?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Stocks
Dr. James Stocks is an urology physician in Cypress, TX, with 15 years of NPI registration. Based on federal Medicare data, Dr. Stocks performed 47,428 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Stocks received a total of $5,783 from 37 pharmaceutical and/or device companies across 187 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Stocks is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years of NPI registration
▲ Top 1% volume in TX
$5,783 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗47,428
Medicare services
Top 1% in TX for urology physician
Not available
Unique patients (not deduplicated)
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Testosterone injection An injection of testosterone cypionate, a form of testosterone hormone. The dose is measured in milligrams. |
37,328 | $0 | $0 |
| Infectious disease DNA/RNA test A laboratory test that uses a specific technique to detect the genetic material of an organism. This method amplifies the target DNA or RNA to identify the presence of the organism. |
3,094 | $34 | $68 |
| Genetic analysis to identify organisms A laboratory test that uses genetic analysis and an amplified probe technique to identify specific organisms. |
1,596 | $34 | $88 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
761 | $3 | $11 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
746 | $102 | $395 |
| Yeast/candida DNA test A laboratory test that uses an amplified probe technique to detect the presence of Candida species, a type of yeast, in a patient sample. |
716 | $34 | $81 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
664 | $64 | $257 |
| Nucleic acid test for multiple organisms A laboratory test that uses amplified probe techniques to detect the genetic material of multiple organisms in a sample. |
399 | $68 | $175 |
| Group B Strep DNA test A laboratory test that uses DNA amplification to detect the presence of Group B Streptococcus bacteria. |
351 | $34 | $81 |
| Staphylococcus aureus DNA test A laboratory test that uses DNA amplification to detect the presence of Staphylococcus aureus bacteria in a sample. |
349 | $34 | $77 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
297 | $8 | $38 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
252 | $11 | $73 |
| MRSA nucleic acid detection test A laboratory test that uses amplified probe techniques to detect the genetic material of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. |
141 | $34 | $87 |
| VRE nucleic acid detection test A laboratory test that uses amplified probe techniques to detect vancomycin-resistant Enterococcus (VRE) DNA in a patient sample. |
137 | $34 | $87 |
| Strep A nucleic acid amplification test A laboratory test that uses nucleic acid amplification to detect the presence of Group A Streptococcus bacteria. This method identifies the genetic material of the bacteria to determine if an infection is present. |
133 | $34 | $88 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
119 | $63 | $238 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
103 | $128 | $516 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
61 | $192 | $718 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
61 | $104 | $400 |
| Endoscopic destruction of bladder/urethra growth, less than 0.5 cm A procedure to remove abnormal tissue growths from the bladder or urethra using an endoscope. This specific code applies when the growths are smaller than 0.5 centimeters. |
47 | $629 | $2,383 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
34 | $63 | $323 |
| Complicated insertion of bladder tube | 24 | $118 | $458 |
| Laser vaporization of prostate A procedure that uses a laser to remove excess prostate tissue through an endoscope. The process includes controlling any bleeding that occurs during the treatment. |
15 | $538 | $4,434 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$5,783
Total received (2018-2024)
Avg $826/year across 7 years
Top 34% in TX for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
187
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,046
2023
$1,384
2022
$1,189
2021
$460
2020
$539
2019
$453
2018
$711
Payments by company (2024)
PROCEPT BioRobotics Corporation
$356
ConvaTec Inc.
$179
Endo USA, Inc.
$110
Antares Pharma, Inc.
$70
Myriad Genetic Laboratories, Inc.
$63
Agiliti Surgical, Inc.
$53
180 Medical, Inc.
$49
COLOPLAST CORP
$48
Olympus America Inc.
$38
Endo Pharmaceuticals Inc.
$34
Sumitomo Pharma America, Inc.
$24
Axonics, Inc.
$23
Top 3 companies account for 61.6% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$933
Coloplast Corp
$822
Myriad Genetic Laboratories, Inc.
$689
PROCEPT BioRobotics Corporation
$615
Endo Pharmaceuticals Inc.
$416
ConvaTec Inc.
$272
Boston Scientific Corporation
$227
Antares Pharma, Inc.
$213
Axonics, Inc.
$119
Agiliti Surgical, Inc.
$112
Endo USA, Inc.
$110
Intuitive Surgical, Inc.
$94
McKesson Medical-Surgical, Inc.
$94
PFIZER INC.
$91
Myovant Sciences Inc.
$81
UROVANT SCIENCES INC
$70
Hollister Incorporated
$69
COLOPLAST CORP
$64
AbbVie Inc.
$62
Olympus America Inc.
$54
Sumitomo Pharma America, Inc.
$51
Cook Medical LLC
$51
ABC Home Medical Supply, Inc.
$50
180 Medical, Inc.
$49
UroGen Pharma, Inc.
$48
Kowa Pharmaceuticals America, Inc.
$44
Medtronic, Inc.
$39
C. R. Bard, Inc. & Subsidiaries
$37
Ambu Inc.
$34
Mission Pharmacal Company
$32
Smith+Nephew, Inc.
$26
Silk Road Medical, Inc.
$22
Janssen Biotech, Inc.
$21
Pacira Pharmaceuticals Incorporated
$20
Acerus Pharmaceuticals Corporation
$19
UROGEN PHARMA, INC.
$17
BOSTON SCIENTIFIC CORPORATION
$17
Top 3 companies account for 42.3% of all-time payments
Associated products mentioned in payments ›
ALTIS · AQUABEAM ROBOTIC SYSTEM · AQUABEAM SYSTEM · AQUACEL FOAM · AVEED · Altis · AquaBeam Robotic System · Axonics · BOTOX · BRAC CDx · BRACANALYSIS CDX · BRACAnalysis CDx · Bard Urinary Drainage Bag · CURE CATHETER · CURE DEXTRA · Cook Medical Urology · Da Vinci Surgical System · ENROUTE Transcarotid Neuroprotection System · Exparel · FEMALE INCONTINENCE · GEMTESA · GENERAL BPH · GENERAL - BPH · GENTLECATH · GENTLECATH GLIDE · General - Kidney Stone Disease · INTERSTIM · Infyna Chic · JELMYTO · LITHOVUE · LUPRON DEPOT · MYRBETRIQ · Myrbetriq · NOCDURNA · Natesto · ORGOVYX · OTREXUP · Onli · PENILE & TESTICULAR RECONSTRUCTN · PROLARIS · REZUM · Rezum Generator · SEGLENTIS · SWISS LITHOCLAST TRILOGY · Seglentis · Sonablate HIFU · SpaceOAR VUE System - 10mL · SpeediCath · Stravix · TOVIAZ · Titan · URIBEL · Uribel · VaPro Plus Pocket · XIAFLEX · XTANDI · XYOSTED · Xtandi · iTIND System
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Urology physicians in nearby ZIP areas
80
County median income
$73,104
Nearest hospital to ZIP centroid (approximate)
LONE STAR BEHAVIORAL HEALTH CYPRESS
5.7 mi
5.7 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Stocks is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Stocks experienced with testosterone injection?
Based on Medicare claims data, Dr. Stocks performed 37,328 testosterone injection services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Stocks receive payments from pharmaceutical companies?
Yes. Dr. Stocks received a total of $5,783 from 37 companies across 187 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Stocks's costs compare to other urology physicians in Cypress?
Dr. Stocks's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Stocks) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Cypress
Browse urology physicians in Cypress ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in TX
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in TX
Which TX urology physicians receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Coloplast Corp Payments to Doctors
See all physicians who received payments from Coloplast Corp.
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology